Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Please note the dates of filing and of when stock began to move

I have noticed there are 2 dates of the filing info. One date is the date on the document of 8-10 and then another date that shows up in PR stuff that is 8-16 ( this is for the public IMO who are even bothering to look). Note how the stock started to move up on 8-10..... what a coincidence, LOL

I can't post a chart but you can go to a stock site and see the up day of 8-10 with low volume. However on the 5th and 9th there are days of higher volume than the 10th. Also note that the date of BaNosser's Ex Parte Motion Application was from 8-8-16. It is just interesting to see how things are interconnected in this process IMO. What significance dollar wise to shareholders remains linked to past experience until more is revealed. Any revelations probably will first appear in regulated filings as we have just seen with this 8K. Wondering what DM has been up to as all this other stuff has been going on. As I understand it they have been ready to take action for a long time, just needed the info from DL.

I get there are other issues facing PTSC but this may be a fruitful accomplishment unless DL once again proves the spoiler. Time will tell. (Notice date of 8-10 below) GLTAL

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 10, 2016

PATRIOT SCIENTIFIC CORPORATION

(Exact name of registrant as specified in its charter)

Delaware 000-22182 84-1070278
(State of other jurisdiction
of incorporation)
(Commission File Number) (IRS Employer
Identification No.)
2038 Corte Del Nogal, Suite 141, Carlsbad, CA 92011-1478
(Address of Principal Executive Offices)
Registrant’s telephone number, including area code: (760) 795-8517
Not Applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).

o Soliciting material pursuant to Rule 14A-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Share
New Message
Please login to post a reply